Why the study?
Does intravenous idarubicin improve response rates in previously treated unfavorable non-Hodgkin's lymphoma?
Population
31 patients with previously treated unfavorable non-Hodgkin's lymphoma. Median age 69 years. 20 relapsing…
Design
Cohort
Follow-up
median duration of response 10+ months
Authors
Loading...
Supports idarubicin consideration in relapsed non-Hodgkin lymphoma; leaves open comparative efficacy versus alternatives.
Does intravenous idarubicin improve response rates in previously treated unfavorable non-Hodgkin's lymphoma?
Intravenous idarubicin demonstrates a 43% response rate in previously treated unfavorable non-Hodgkin's lymphoma with manageable cardiac toxicity.
Case et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: